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PERSPECTIVES IN RENAL MEDICINE
Progression of renal damage in human glomerulonephritides:
Is there sleight of hand in winning the game?
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Human glomerulonephritides (GN) remain one of the most
important causes of end-stage kidney disease worldwide [1—6].
Much effort has been expended over the last twenty years trying
to gain a better understanding of the mechanisms involved in the
pathogenesis of this heterogeneous group of renal diseases [7].
The initial events triggering the development of the various
forms of primary GN vary somewhat, as do their histological
features and natural history. However, in the early phases, all GN
are characterized by an inflammatory process mediated by a
number of soluble factors released by activated resident cells
and/or by infiltrating immune cells [71. For this reason, hereafter
we liken glomerular diseases to different card games played by the
same players (resident and infiltrating cells) using the same pack
of cards (the soluble mediators). If the inflammatory process
persists, the renal damage will progress toward renal fibrosis at a
constant rate, independently of the original events; otherwise a
more or less complete recovery may be observed [8]. In short,
some of the games will end at this point while others will enter a
common phase and progress to renal fibrosis.
During the last decade, the explosive development of molecular
biology techniques applied to routine renal biopsy has enabled
identification of most of the cards and their role in the games, and
an understanding of how and when they are used by the different
players [9]. The aim of the present work is to describe what it is
known about the players, the cards they use and their behaviors in
the different games, and to give a perspective on how nephrolo-
gists can influence their game strategy.
THE PLAYERS
In all primary GN we have to consider at least three groups of
players: T cells, monocytes/macrophages and resident glomerular
cells (mesangial, endothelial and epithelial) [10—12]. Although all
of these players are invariably involved in the various games, they
may assume a different role and relevance in each. Indeed, it is
the behavior of the players that makes each game different.
Therefore, to understand the games we first must recognize the
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main features of the players and how they respond to the different
cards.
T cells
T cells act as trumps in the immunological processes involved in
any ON [101. They direct the intervention of the immune system
and even the activation of the resident cells, through the produc-
tion and release of an array of cytokines [13]. However, different
subsets of T lymphocytes may play different pathogenetic roles in
glomerular diseases [14].
CD4 and CD8 are the main markers of the two major subclasses
of mature T cells, helpers and suppressors, which respond differ-
ently to antigen [13]. Over the last few years it has been
demonstrated that the cellular and humoral areas of the specific
immune response are regulated by distinct subsets of T helper
cells, termed type 1 (ThI) and type 2 (Th2) cells [14]. They both
respond to antigenic stimulation with a transient burst of cyto-
kines, that differ in the two subsets [15]. Thi cells primarily
secrete interleukin (IL)-2 and interferon (IFN)-y, whereas Th2
cells produce IL-4, IL-5, IL-b and IL-13 (Fig. 1) [14, 15].
Numerous factors appear to play a role in the polarization of the
Tb cell response toward the Thi or Th2 phenotype, although
cytokines mainly determine this differentiation [16]. Among the
cytokines, IL-12 and IL-4 are the main messages directing the
development of T helper cells toward the Thi and Th2 phenotype,
respectively (Fig. 1) [16]. Thi cells are responsible for cell-
mediated inflammatory reactions characterized by a marked
potentiation of phagocytic cell functions, and also provide help to
some B cells (Fig. 1). Th2 cells, on the other hand, promote the
synthesis of antibodies and inhibit several macrophage functions
(Fig. 1). Thus, Th2 cells seem, to a certain extent, to play a
protective role against the damaging effects of ThI -mediated
immune reactions [14].
In proliferative and progressive ON, in which a delayed hyper-
sensitivity reaction is taking place in glomeruli, the T cells
involved in the immune process are mainly of the ThI type [17,
18]. The Th2 cell response, on the other hand, appears to play a
pathogenetic role in animal models of GN associated with sys-
temic autoimmunity (host-vs.-graft disease in mice and mercury-
induced nephritis in rats) [19].
Monocytes/macrophages
Monocytes, among the cells of the immune system, are surely
those whose presence has most often been described inside the
glomerular tuft and the interstitial space in human GN [10, 20].
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They can also be considered as the real effectors of the immune
system in the pathogenesis of glomerular diseases [11]. Once in
the glomerulus or within the interstitium, monocytes can mediate
the injury through different pathways. They can synthesize and
release a variety of cytokines and growth factors that can, in turn,
attract more infiltrating immune cells and activate resident cells
(Fig. 1) [21]. Thus, monocytes can be described as the players with
the greatest number of cards to be used. Besides the above-
mentioned soluble factors, the activated monocytes/macrophages
have a considerable number of weapons for directly damaging the
glomerular and the interstitial structures [21]. In response to
specific activating stimuli, these infiltrating cells can release free
oxygen radicals and lysosomal enzymes that may endanger the
other players. Although it is now clear that monocytes have an
important part in the pathogenesis of GN, the mechanisms
underlying their influx into the glomeruli and/or the renal inter-
stitium are still largely unknown. However, it can be hypothesized
that they move through the endothelial barrier attracted by the
presence of specific chemotactic factors produced and released by
resident cells or by infiltrating T cells [11].
Fig. 1. Schematic representation of the
regulatory interactions among T helper cell
subsets (Thp, Thi, Th2), B cells (B),
eosinophils (E), mast cells (MC), macrophages
(Mø) and resident renal cells. Signs are: (—)
suppression; (+) induction. The Thi system
modulates cell-mediated immunity and the Th2
system regulates humoral immunity.
Explanation of the other observations are in the
text.
Resident cells
In the past, resident cells were considered only as a static
framework or a passive target for the action of the infiltrating
cells. On the contrary, in the last decade it has been realized that
mesangial, epithelial and endothelial cells are active players in GN
games, participating in different ways in the pathogenesis of any
glomerular disease [12]. They can proliferate in response to a
variety stimuli. This is a particularly relevant trait for mesangial
cells, since there is a group of GN characterized by an increased
proliferation of these resident cells [22]. All may play key roles in
the accumulation of extracellular matrix (ECM), since they can
synthesize both the ECM components and the enzymes that
catalyze ECM degradation. Moreover, they can amplify the
immune-mediated inflammatory process through the synthesis
and release of a variety of chemotactic factors for monocytes and
T cells [23]. Finally, they can further facilitate the migration of the
immune cells into the glomerular tuft, expressing a variety of
adhesion molecules on their surface that favor their interaction
with the infiltrating cells [12]. It is noteworthy that all these
functions are strictly regulated by cytokines and growth factors
IL-12, IFNy
I L-2
IL-i, IL-4
I cells)
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Cell mediated immunity
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locally released by monocytes and T cells or even by the resident
cells themselves. In fact, the latter can produce a relevant number
of growth factors and chemokines including some of the mono-
cyte-specific cytokines [24].
THE CARDS
All the players interact during the games using a common deck
of cards that include a variety of soluble factors. These soluble
mediators, which act as intercellular messengers and carry regu-
latory signals from cell to cell, are mainly cytokines and growth
factors [25]. They can be synthesized and released to influence the
functions of the cell that produced them (autocrine action) [26] or
the functions of the cells in the immediate vicinity (paracrine
action) [27]. Both cytokines and growth factors, by binding specific
cell-surface receptors on the target cell, trigger a cascade of events
that influence cellular functions [25]. Interestingly, all of these
mediators can modulate their own synthesis and secretion as well
as the synthesis and secretion of other cytokines and growth
factors.
In our card game simile it should be assumed that: (1) each
player can use only an assigned number of cards and present the
receptor to bind a limited number of them; (2) each player must
always react to a particular card in the same way, although
different players can respond to the same card in completely
different ways.
Based on their functions and origin, we can divide the cards into
five groups: Thl cytokines, Th2 cytokines, monocyte-derived
cytokines, chemokines and growth factors (Table 1).
Thi cytokines
Thi cytokines are produced mainly but not exclusively by Thi
cells and present powerful pro-inflammatory effects both in the
systemic circulation and within the kidney. Indeed, they activate
monocyte/macrophages, T cells themselves as well as resident
renal cells [15, 28]. The two most important cytokines belonging
to this group are IL-2 and IFN-y (Fig. 1).
Interleukin-2. Interleukin-2 (IL-2) is produced by Thi and
CD8 + lymphocytes, and functions as an autocrine T cell growth
factor [26]. It activates T cells and stimulates their growth, giving
rise to their clonal expansion [28]. Thus, IL-2 plays a key role in
the delayed-type hypersensitivity response [15].
Interferon-y. On the other hand, INF-y primarily exerts an
activating effect on monocytes and resident cells [29]. It induces
MFIC class I and II antigen expression, modulates tumor necrosis
factor (TNF) receptors on monocytes and stimulates the synthesis
and release of chemokines and growth factors by endothelial,
mesangial and epithelial cells [30—32]. Moreover, IFN-y inhibits
the growth and activation of Th2 cells (Fig. 1) [28].
Th2 cytokines
Th2 cytokines have mostly inhibitory effects on monocytes!
macrophages and on Thi cells [16]. However, they can switch on
humoral immunity through direct activation of B lymphocytes
(Fig. 1). Moreover, they can modulate some functions of resident
renal cells such as adhesion molecule expression [33].
Interleukin-4. Interleukin-4 is a glycoprotein produced by acti-
vated Th2 lymphocytes; it exerts its biological activity on resting T
cells, B cells, macrophages, endothelial and mesenchymal cells
[34—37]. This cytokine has been shown to increase MHC class II
antigen expression and antibody production in resting B cells [38]
Molecular Sources Targets
Cytokine wt (kD) (cells) (cells) Effects
IL-6 21—28 Monocyte
T cell
Mesangial
Epithelial
Endothelial
MCP-1 14—21 Mesangial
Epithelial
Endothelial
Monocyte
RANTES 6—8 T cell
Mesangial
Epithelial
IL-8 8 Mesangial
Monocyte
PDGF 30—34 Mesangial
Endothelial
Epithelial
Monocyte
TGF-13 25 Endothelial
Mesangial
Epithelial
Monocyte
bFGF 16—24 Endothelial
Mesangial
EGF
-Clonal expansion
-MHC, chemokine
and growth
factor induction
-Inhibition of Th2
-MHC II and
antibodies
induction
-Proliferation
-Inhibition of Th2
and monocyte
-Inhibition of Thi
and monocyte
-B cell activation
-Inhibition of Thi,
B cell and
monocyte
-Activation
-Cytokine induction
-Apoptosis
and the proliferation of T cells directly and by increasing the
production of IL-2 or the expression of IL-2 receptor [34, 39]. IL-4
increases endothelial cell adhesiveness to T cells by inducing
adhesion molecules [33], while it has an anti-inflammatory effect
on monocytes, inhibiting the production of IL-1f3, TNFw, IL-6 and
Table 1. The cards
IL-2 15 Thi,TCD8+ Tcell
IFN-y 20—25 Thi Monocyte
Epithelial
Endothelial
Mesangial
IL-4 18—20 Th2 T cell, B cell
Monocyte
Mesenchymal
Endothelial
IL-lO 35—40 Th2 Thi
Monocyte Monocyte
B cell B cell
IL-13 10 Th2 Thi
Monocyte
B cell
TNF-a 17 Monocyte Monocyte
Mesangial
Endothelial
IL-i 18 Monocyte Monocyte
Mesangial Mesangial
Endothelial
Epithelial
Mesangial
Epithelial
T cell
Monocyte
-Chemotaxis
-Proliferation
-Chemokine and
growth factor
induction
-Proliferation
-Cytokine induction
(IL-2)
-Chemotaxis and
activation
-Chemotaxis and
activation
T cell
Neutrophil -Chemotaxis and
activation
Mesenchymal -Proliferation
-Chemotaxis
-Growth factor
induction
Endothelial -Extracellular matrix
Epithelial synthesis
Mesangial -Growth inhibition
Monocyte
Mesangial -Proliferation
Endothelial -Growth factor
induction
6 Epithelial Epithelial
Endothelial
Mesangial
-Proliferation
-Growth factor
induction
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IL-8 and reducing the expression of Fcy receptor (Fig. 1) [37, 40,
41]. Moreover, this cytokine can stimulate the proliferation of
cells of mesenchymal origin. Finally, IL-4, together with IL-b and
IL-13, inhibits the expansion of Thi cells [15].
Interleukin-lO. Interleukin-lO is produced upon immune activa-
tion by Th2 cells, monocytes/macrophages and B cells [42]. It
suppresses both cytokine production and antigen specific prolif-
eration of cultured Thi clones. Thus, IL-b reduces delayed-type
hypersensitivity reactions and other Thi cell-mediated responses
[42]. It also inhibits the production by monocytes/macrophages of
important inflammatory mediators like IL-la, IL-6, IL-8, TNF-a.
On the other hand, it exerts a stimulatory effect on B cells and
mast cells [42]. Recently Del Prete et a! have shown that IL-b is
produced by both Thl and Th2 cells in the human system and that
it down-regulates IFN-y production by Thi cells and IL-4 and
IL-5 production by Th2 cells [43].
Interleukin-13. Interleukin-13 is a potent modulator of human
monocyte and B cell functions. It is produced early and over
prolonged periods by human Th2 cells following activation, and
acts like IL-4 in suppressing the development of Th 1 cells, thus
favoring the generation of Th2 developmental pathways [reviewed
in 44]. IL-13 inhibits the production of chemokines by human
monocytes stimulated with LPS and enhances the monocyte
expression of several members of the integrin superfamily and of
MHC class II antigens [44].
Monocyte-derived cytokines
Activated monocytes can synthesize a variety of soluble medi-
ators. Among them the most specific for the monocytic cell line
are IL-I, IL-6 and TNF-a (Fig. 1)1111.
Tumor necrosis factor-a. This is produced mainly by monocytes/
macrophages, but it can also be synthesized by lymphocytes [45].
Various different biological activities of TNF-a could be relevant
in the pathogenesis of GN, including: (1) induction of mesangial
cell contraction and proliferation; (2) monocyte and lymphocyte
recruitment and activation directly and through the increased
synthesis and release of chemokines and lipid mediators by renal
resident cells; (3) amplification of the inflammatory response by
inducing the production of prostaglandins, nitric oxide, free
oxygen radicals and the expression of the MHC class I and II
antigens in renal cells; (4) increased cell apoptosis by decreasing
the mRNA levels of apoptosis-preventing gene bcl-2 while in-
creasing the expression of apoptosis-inducing gene Fas in target
cells [46—48].
Interleukin-1. Interleukin-1 is a pleiotropic cytokine that is
primarily released by activated monocytes/macrophages and res-
ident cells [49—52]. Two different forms of IL-i have been
observed in humans, IL-la and IL-1f3, that present a different
pattern of glycosylation and exert a variety of biological effects on
different cell types [51]. Some IL-I activities include induction of
chemotaxis in polymorphonuclear cells and macrophages, prolif-
eration of mesangial and endothelial cells and stimulation of
chemokine and growth factor production by resident renal cells
[53, 54]. This cytokine also induces the production of factors
required for T cell activation and proliferation [55].
Interleukin-6. Interleukin-6 is produced not only by activated
monocytes/macrophages, but also by T cells, endothelial and
mesangial cells. It exerts its biological effects on a variety of target
cells including resident glomerular and tubular cells [56]. IL-6 acts
as a second signal for the production of IL-2 promoting the IL-2
dependent proliferation of T lymphocytes [57]. It induces prolif-
eration of mesangial cells in vitro as well as in vivo [581. IL-6
production is rapidly and transiently induced by other cytokines
including IL-I and TNF-a. Functional interaction between IFN-y
and TN F-a is involved in the regulation of IL-6 and IL-6 receptor
expression in monocytes [59].
Chemokines
The chemotactic cytokines or chemokines play a pivotal role in
the local dealing out of the inflammatory response, ensuring that
the correct immune effector cells are recruited and activated in
the right place, at the right time [60, 61]. Chemokines act as
magnets for white blood cells and thus contribute to lymphocyte,
granulocyte and monocyte infiltration and activation within gb-
meruli and interstitium. The migration of leukocytes to the
interstitial tissue compartment is due to the adhesion of these cells
to the endothelium and their passage through endothelial cell
junctions and basement membrane. As to their action, chemo-
kines bind the extracellular matrix components and attract the
immune cells by haptotaxis (movement of target cells through a
gradient of an immobilized attractant) [60]. Therefore, concen-
tration of chemokines in the subendothelial matrix is essential for
extravasation and migration of leukocytes. Among the proteins
belonging to this family, attention has recently been focused on
three molecules: tL-8, monocyte chemotactic peptide-l (MCP-l)
and regulated on activation normal T cells expressed and secreted
factor (RANTES). These have different specificity for various
immune cells: IL-8 is a powerful chemoattractant for neutrophils,
while MCP-1 and RANTES act specifically on monocytes and
lymphocytes, respectively [60, 62]. The production of these three
chemokines is induced by cytokines, such as IFN-y, IL-la and /3,
TNF-a [23, 31, 63—65], and by other pro-inflammatory stimuli like
reactive oxygen species, IgG, LDL and thrombin in renal resident
cells and in infiltrating immune cells [66—71].
Growth factors
Growth factors are normally involved in development, in many
physiological regenerative processes and in tissue repair after
injury. Due to their specific effects, it has been suggested that
some of them may be involved in the pathogenesis of renal
damage in human GN [24].
Platelet-derived growth factor. Platelet-derived growth factor
(PDGF) is a cationic protein, constituted by two chains (A and B)
that can be combined in three different isoforms (AA, AB and
BB) [72]. The PDGF receptor also consists of an a and a /3 subunit
[72]. The former binds either A or B chains whereas the latter
binds only the B chain. Initially recognized as a product of the
alpha granules of platelets, PDGF is synthesized and released by
circulating immune cells, activated resident glomerular cells and
smooth muscle cells [reviewed in 24]. PDGF is the most potent
mitogen for mesenchymal cells including mesangial cells [73].
Moreover, most of the mitogenic factors induce its production,
suggesting a possible autocrine effect of PDGF in their prolifer-
ative effect [73]. Besides proliferation, PDGF can induce ECM
component expression and the contraction and migration of both
mesangial cells and smooth muscle cells [72]. Many stimuli induce
mesangial and endothelial cell production of PDGF including
basic fibroblast growth factor (bFGF), epidermal growth factor
(EGF), endothelin, thrombin and PDGF itself [73—75].
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Transforming growth factor. Transforming growth factor
(TGF)-13 consists of three isoforms (131, J32 and 133) and is
produced by monocytes and resident cells [76]. It is secreted
bound to a latency-associated peptide in an inactive form that
requires activation before it can exert its biological effect. In vitro,
the inactive form can be activated by removing the latency-
associated peptide with acid treatment or proteases, but nothing is
yet known about the activation mechanism in vivo [76]. TGF-13
binds three specific cell-surface receptors (I, II and III). All of the
resident cells express at least one of the receptors and respond to
TGF-J3. Its main effect is to stimulate ECM accumulation by
increasing the synthesis and deposition of the ECM components
and by reducing matrix turnover, through the inhibition of the
enzymes that catalyze ECM degradation (metalloproteinases) [76,
77]. In addition, TGF-13 has a potent antiproliferative action and,
interestingly, an inhibitory effect on immune system activation
[76]. Indeed, TGF-p knock-out mice develop a systemic autoim-
mune disease [78].
Basic fibroblast growth factor. Basic fibroblast growth factor
(bFGF) is a peptide, belonging to the small family of heparin-
binding growth factors, which exerts, both in vitro and in vivo, a
mitogenic effect on a variety of cell types including mesangial,
endothelial and epithelial cells, smooth muscle cells and fibro-
blasts [79]. It is considered one of the most potent angiogenic
factors [80]. bFGF has two very peculiar features. It does not
present a signal peptide bringing the protein from the Golgi
system to the membrane, so that its mechanism of secretion is still
largely unclear. Moreover, once bound to the receptor and
internalized, it is slowly degraded to low molecular weight pep-
tides that may persist and exert their action for up to 24 hours
inside the cell [81].
Epithelial growth factor. Epithelial growth factor (EGF) acts not
only on epithelial cells, but also on endothelial and mesangial cells
[73]. The kidney is a significant site of EGF synthesis, as specific
binding sites have been found in the glomeruli and in different
segments of the tubules [82]. This peptide is a trophic factor for
renal tubular cells and it plays a key role in regenerative phenom-
ena during recovery from tubular damage [83].
THE GAMES
Minimal c!ange disease
Minimal change disease (MCD) is the most common cause of
primary nephrotic syndrome in children, accounting for 75 to 77%
of all cases [84, 85], while in adults it represents less than 25% of
all primary nephrotic syndromes [86]. Its pathogenesis remains
unknown, although some evidence in favor of an immune patho-
genetic disorder has been reported. Indeed, the association of
MCD with athopy to different antigens, high serum IgE levels and
an increase of Fc receptor for IgE on B cells is frequent [87]. The
beneficial effects of immunosuppressors (such as corticosteroids,
cyclophosphamide, etc.) or of immuno-stimulants (that is, levami-
sole) seem to corroborate the hypothesis that an allergen may
trigger the immunological disorder responsible for MCD. An
increase of glomerular capillary permeability to serum proteins,
mainly to albumin, is the hallmark of this disease. No evident
glomerular alterations can be seen on light microscopy, whereas
foot process fusion and detachment of epithelial cells from the
glomerular basement membrane (GBM) are evident on electron
microscopy. The loss or the charge alteration of heparan sulphate
proteoglycan costituents found, by immunohistochemistry, at the
glomerular level are probably responsible for the altered glomer-
ular capillary charge-dependent permselectivity of MCD [88—90].
On the basis of this evidence, the question "Does an abnormal
immune response induce an alteration of glomerular permeabil-
ity?" deserves an answer. A T cell defect, characterized by a
decreased number of Thi cells and increased number of Th2 cells,
has been reported in children with MCD [91]. Moreover, in
children with primary nephrotic syndrome, Stachowski et al
demonstrated a shift from Thi to Th2 subsets of CD4+ T cells,
cultured with autologous monocytes, and an increased production
of IL-4, IL-6 and IL-b [92]. Furthermore, Neuhaus et al found
that calcium ionophore stimulation of peripheral blood lympho-
cytes from children with relapsed MCD caused the release of
large amounts of IL-4 [93]. Bakker et al demonstrated that
infusing lymphoid cells from MCD patients in rats caused an
increased glomerular permeability [94]. Thus, on the basis of
these observations, it is possible that the old pathogenetic hypoth-
esis made by Shaloub [95] that considered MCD as a T cell
disorder is still applicable. The prevalence of a T cell subpopula-
tion, during onset or relapse of the disease, may induce an
increased production of specific cytokine(s), responsible for the
glomerular charge-selectivity barrier alterations leading to pro-
teinuria. Several investigators [96—98] have shown a production of
a vascular permeability factor by stimulated and unstimulated
peripheral blood lymphocytes from patients with MCD. Recently,
Koyama et al reported that T cell hybridomas obtained from
patients with MCD produce a glomerular permeability factor with
properties similar to TNF-a [99]. This factor infused into rats
induced massive proteinuria due to a partial fusion of glomerular
epithelial cells and to the altered electron microscopic distribution
of anionic charges. Moreover, Saxena and others [100, 101] found
high levels of IL-i and IL-2 in supernants of cultured activated
lymphocytes from patients with MCD. Furthermore, an increased
production of IL-8 has been found in peripheral blood mononu-
clear cells from patients with relapsing MCD [102]. Bricio et al
have also demonstrated an increased production of IL-i in
cultured whole glomeruli obtained from rats with adriamycin-
induced nephrotic syndrome [103]. In this case, the augmented
production of IL-i was primarily related to the glomerular
macrophage infiltration and less to mesangial cell activation.
Indeed, in this rat model of nephrotic syndrome, proteinuria was
strictly correlated with the number of Ia-bearing infiltrating cells.
Finally, indirect evidence of cytokine involvement in the patho-
genesis of proteinuria in MCD is provided by development of a
nephrotic syndrome in patients with various malignancies treated
with recombinant IL-2 as an immunotherapy [104].
Focal segmental glomeruloscierosis
Idiopathic focal segmental glomeruloscierosis (FSGS) is an-
other common cause of nephrotic syndrome in children and young
adults [105]. Recently, it has been hypothesized that in patients
with FSGS the presence of a circulating factor may alter the
glomerular barrier to protein filtration [106]. This hypothesis is
corroborated by the evidence that some patients with FSGS
respond to therapy with plasmapheresis [107, 1081 and in 20 to
40% of them FSGS recurs after transplantation [109]. Indeed,
Savin et al have reported the presence of a serum factor that
increases the glomerular permeability to albumin in transplanted
patients with recurrent FSGS [110]. The presence of this factor
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was demonstrated by incubating isolated human glomeruli with
fractions of serum obtained from discarded plasma, separated by
plasmapheresis, in six different patients. Although this finding
may be an indirect evidence due to the technique used, the validity
of the method in measuring increased glomerular permeability to
albumin has previously been demonstrated in experiments where
isolated murine glomeruli were incubated with protamine [1111,
superoxide [112], activated leukocytes [113] or Heymann antibody
and complement [1141. In its active form, the 50 kDa serum factor
binds to protein A and has a weak anionic charge at pH 6.0. It is
assumed to be a nonimmunoglobulin protein or a fragment of an
immunoglobulin and its activity is concentration dependent. This
factor has a potent activity comparable to a cytokine-like mole-
cule. Indeed, few nanograms of it cause direct injury to podocytes.
It can be hypothesized that the circulating factor, present in
recurrent FSGS after renal transplantation, could interact with
the podocytes leading to the retraction and flattening of the
foot-processes and to their detachment from the basal membrane
[115]. Within several weeks after successful plasmapheresis, the
podocytes revert to a normal electron microscopic morphology,
and this reversible change in shape could be related to the
reorganization of the podocyte cytoskeleton [1081. However, if a
serum factor is responsible for the glomerular damage, why are
sclerotic lesions focal and segmental instead of diffuse? A recent
paper published by Fuiano et al seems to provide an answer to this
question [116]. The morphological analysis of serial sections of
renal biopsy specimens obtained from patients with FSGS dem-
onstrated that the distribution of sclerotic lesions is not focal but
diffuse [116]. Thus, this study supports the hypothesis that a
circulating factor may damage all glomeruli although only some of
them show lesions evident in a routine histological study. If the
presence of this serum factor can explain the detachment of
podocytes from the GBM and the glomerular sclerosis by means
of a collapse phenomenon, then which factors drive this process
and the development of interstitial fibrosis in FSGS? Stein-Oakley
et al have recently reported an overexpression of TGF-13, PDGF
and PDGF receptors both at the glomerular and at the interstitial
level in human FSGS, suggesting that the combined action of both
these growth factors could induce the fibrotic glomerular and
interstitial histological changes observed in this GN [117].
Recent advances in the understanding of the pathogenesis of
HIV-associated FSGS have shown that viral proteins, like HIV
Tat, might be toxic to visceral epithelial cells or might induce the
release of growth factors such as TGF-J3 and FGF, as observed in
Tat transgenic mice and in human HIV-associated nephropathy
[118—120]. Therefore, it is conceivable that other viruses, not yet
identified, could play a similar pathogenetic role in those form of
FSGS currently defined idiopathic.
Membranous glomerulonephritis
Membranous glomerulonephritis (MGN) is characterized by
the presence of small subepithelial immune deposits in the lamina
rara externa of the GBM that progress to large size deposits
incapsulated in the GBM matrix [8]. The distruption of the GBM
structure increases its permeability to albumin and other serum
proteins, which then form the massive proteinuria. Approximately
25 to 50% of patients progress to end-stage kidney disease over 10
years [71. Heymann nephritis, an experimental model induced in
rats, closely mimics the morphologic changes of the GBM and the
chronic course of the human disease [121, 1221. In passive
Heymann nephritis, immune complexes are formed in situ as the
result of interaction between administered antibodies and gp 330,
a glycoprotein antigen present in clathrin-coated pits on the base
of podocyte foot processes, and a 44 kDa receptor-associated
protein [123—126]. In human membranous nephritis, different
antigens have been postulated as being responsible for the
immune complex formation in the blood or kidney. Recently,
several reports described the association of hepatitis C virus with
MGN [127]. The subepithelial immune complexes activate the
complement system leading to the formation of the terminal
complement complex C5b-9 that is deposited along the GBM,
endocytosed by glomerular epithelial cells, and finally transported
into the urinary space [128—130]. Activation of the complement
cascade has also been demonstrated by the presence of C3dg in
the urine [131]. Urinary excretion of C5b-9 correlates with
immunologic activity of disease in both Heyman nephritis [132]
and in patients with membranous nephritis [131]. In the latter,
high initial urinary excretion is associated with a progressive
clinical course of the disease [131].
The mechanism by which C5b-9 increases the glomerular
permeability to macromolecules is poorly understood. However,
in vitro studies have shown that C5b-9 causes the release of
reactive oxygen species (ROS), IL-1/3 and TNF from mesangial
cells [133, 134]. Histochemical studies localized ROS in podocytes
within cytoplasmic membrane vesicles and along the foot process
membranes in passive Heymann nephritis [135]. The authors
hypothesized that C5b-9 stimulates the de novo synthesis of the
NADPH-oxidoreductase complex by podocytes, which in turn
become able to generate ROS. Lipid peroxidation in GBM,
induced by ROS, could promote dimerization of type IV collagen,
distortion of GBM structure, alterations in the glomerular filtra-
tion barrier and consequently proteinuria [135].
Other effects of C5b-9 on glomerular epithelial cells are
probably directed toward the synthesis of cytokines and growth
factors. TNF-a has been demonstrated in glomerular epithelial
cells in human MGN and the integral cytokine is found in urine
[136, 137]. Significantly elevated urinary levels of IL-lp are also
reported in MGN in correlation with increased urinary elimina-
tion of the complement regulatory protein CD59 [138].
On the other hand, TGF-/3 seems to mediate ECM accumula-
tion in experimental membranous nephropathy. Rats affected by
passive Heymann nephritis show a significantly increased glomer-
ular expression of TGF-p2 and TGF-133, in association with
development of proteinuria. The expression of these TGF-3
isoforms by glomerular epithelial cells parallels the up-regulation
of TGF-p receptor type I and II on the same cells. Complement
depletion, by preventing C5b-9 deposition, inhibits TGF-13 protein
and receptor up-regulation [139].
Membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis (MPGN) is a
chronic progressive disease with a poor prognosis that occurs in
older children and young adults [7]. Its pathogenesis is not
completely understood. Over the past three years, several papers
have reported the frequent association of this disease with hepa-
titis C virus infection, presence of circulating immune complexes,
and often with the characteristics of cryoglobulins [140, 141]. This
nephritis also occurs in a variety of diseases caused by chronic
bacterial, viral, parasitic infections, autoimmune disorders or
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primary or malignant hemopathies [142]. The renal manifesta-
tions are proteinuria, often in the nephrotic range, hematuria, and
some degree of functional impairment and hypertension. Acute
nephritic syndrome may be observed.
The light microscopic picture is characterized by mesangial cell
proliferation and duplication and/or thickening of the capillary
basement membrane. On the basis of ultrastructural morphology,
three types have been described: type I, with subendothelial
deposits; type II, with intramembranous dense deposits (dense
deposit disease); and type III, a variant of type I, with subendo-
thelial and subepithelial deposits associated with glomerular
capillary basement membrane disruption. Type I, the most com-
mon form of MPGN, is probably mediated by glomerular depo-
sition of circulating immune complexes with activation of the
classic complement pathway. In type II, the occurrence of ne-
phritic factors induces the involvement of the alternative pathway.
In type III, hypocomplementemia is infrequent and the pathogen-
esis is poorly understood [7].
Monocytes-macrophages play an important role in this disease
[201. These cells are present in mesangium during the active
injury, and move to the glomerular capillary wall attracted by
chemotactic factors produced by the endothelium after immune
complexes have formed in situ or been deposited from the
circulation. During the active phase of the disease the stimulated
endothelial cells produce a new basement membrane-like struc-
ture separated from the original lamina rara by the presence of
deposited immune complexes and trapped inflammatory cells.
This repair process completes the double contour of the glomer-
ular capillary wall, named the "tram track." During the course of
the disease either the inflammatory attacks or the repair process
will predominate [7].
The chronological changes in intraglomerular CR1, CR3 and
CR4 expression, as well as intraglomerular C3c deposition have
been studied in serially biopsied cases of MPGN type I. Data
reported by Soma et al [143] showed a marked glomerular
infiltration of CR3 + and CR4+ cells (monocytes/macrophages
and granulocytes) that correlated with the amount of glomerular
C3c deposits. This result, and the fact that C3b is a ligand of these
tWo adhesion molecules belonging to the /32 integrin family,
indicate that the accumulation of leukocytes in glomeruli of
MPGN is partly promoted by the adhesive effect, in a /32 integrin-
and complement-dependent fashion. CR1 expression is a signifi-
cant prognostic factor of MPGN type I, and the risk of renal
deterioration is notably reduced in those patients with normal or
decreased CR1. Some authors have also reported an interaction
between intraglomerular T lymphocytes and monocytes/macro-
phages with continuous C3c deposition and an adverse outcome
[143, 144].
IgA nephropathy
IgA nephropathy (IgAN) is a mesangioproliferative GN char-
acterized by granular deposits of IgA and C3 in the mesangium.
This disease is the most frequent form of primary GN causing
end-stage renal disease among Caucasoids and Orientals. It is
characterized by recurrent episodes of gross hematuria associated
with upper respiratory tract infections and/or persistent microhe-
maturia with proteinuria. IgAN is an indolent, chronic GN that
may gradually progress to renal failure. The renal survival curves
show 10 to 20% of the patients reaching end-stage renal disease
after 10 years from the apparent clinical onset of the disease and
20 to 50% after 20 years [145].
Undoubtedly, mesangial cells play a pivotal role in IgAN, since
their proliferation and activation surely is certainly a critical step
in the pathogenesis of this GN [7]. It is well known that PDGF
stimulates mesangial cell proliferation both in vitro and in vivo
[146, 147]. Interestingly, we demonstrated an increased expression
of PDGF AB within the glomeruli in this GN, while we observed
an increased PDGF (3 receptor expression at the glomerular as
well as at the interstitial level [148, 149]. The increased expression
of PDGF and its receptor strictly correlated with the degree of
mesangial and interstitial cell proliferation and with the extent of
glomeruloscierosis and interstitial fibrosis [148, 149]. Besides
PDGF, IL-6 has also been suggested to induce mesangial cell
activation [56]. Indeed, several authors have demonstrated an
up-regulation of IL-6 within the glomeruli, while we observed a
striking up-regulation of IL-6 gene and protein expression in the
tubulointerstitium [58, 150, 151]. Moreover, we reported an
increased IL-6 urine excretion, strictly correlated with its renal
tissue expression, suggesting the urinary presence of this cytokine
as a possible marker of disease activity [151]. IL-4, a cytokine
produced by infiltrating CD4 + T cells, may also be involved in
turning on mesangial cells [150, 152].
The expansion of the mesangial and interstitial matrix is
another histological feature of IgAN. The data obtained from in
vitro studies would indicate TGF-/3 as the factor inducing these
fibrotic changes [76]. Instead, studies on human disease are
contradictory. In fact, Ballardie et al reported decreased TGF-/3
expression and concluded that reduction of this anti-mitogenic
growth factor might allow the proliferation of mesangial cells
[1501. In contrast, Yamamoto et al demonstrated a significant
increase of all three TGF-(3 isoforms associated with the increase
in ECM deposition [153].
The third histopathologic feature of IgAN is the presence of
macrophage infiltration in the interstitium and particularly in
periglomerular areas [20]. There is now increasing evidence that
the mediator recruiting these cells could be MCP-1. We reported
an increase in MCP-1 gene and protein expression in human
IgAN, correlated with the extent of monocyte infiltration [154].
Resident cells expressing the chemokine were mainly proximal
tubular cells and glomerular parietal epithelial cells. Moreover,
like IL-6, MCP-1 urinary excretion also mirrored the tissue
expression, suggesting that this could be used as a marker of
disease activity in the follow-up for IgAN patients.
In the progressive form of this GN, tubular cells are constantly
involved in progression toward fibrosis. If on the one hand they
can be activated and produce pro-inflammatory cytokines, on the
other their functions and trophism may also be greatly altered.
EGF is the main factor regulating tubular cell growth and/or
regeneration [83]. We observed a significant decrease in EGF
expression in IgAN patients with moderate and severe histologic
damage, mainly characterized by interstitial fibrosis and tubular
atrophy, indicating this factor as a reliable marker of tubular
impairment that can be easily detected in the urine [151].
Crescentic glomerulonephritis
Crescentic glomerulonephritis (CGN) is the most aggressive
form of renal disease, and rapidly progresses to end-stage renal
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failure. It can occur without systemic manifestations, in combina-
tion with diffuse pulmonary hemorrhage (Goodpasture's syn-
drome) or in the presence of diffuse necrotising vasculitis. In the
first case, granular deposits of immunoglobulin and complement
are found in the glomeruli. In the second, there are linear IgG
deposits along the GBM and in the third, often associated with
circulating antineutrophil cytoplasmic antibodies, no immune
deposits can be observed within the glomerular tuft [71.
Examination of renal biopsies performed in patients with CGN
showed a significant leukocyte infiltration at glomerular level. The
presence of CD4 + and CD8 + T cells and monocytes/macro-
phages suggested the occurrence of a delayed-type hypersensitiv-
ity reaction [155]. In favor of this hypothesis, a major susceptibility
to CGN has been observed in rat strains with a predominantly
Thi response to antigens [156]. A linear correlation between the
number of T lymphocytes and the number of monocytes in the
glomeruli indicates the importance of T cells in the recruitment of
monocytes/macrophages in cell mediated immunity [157, 158].
Neale et al also demonstrated a correlation between the presence
of crescents with fibrin deposits and the increased number of
intraglomerular IL-2R + mononuclear cells and decreased creat-
mine clearance [159]. Li et al found that T lymphocytes and
macrophages in glomeruli with active crescents correlated with an
increased number of intraglomerular IL-2R mononuclear cells
and decreased creatinine clearance [160].
T cells and monocytes can be therefore considered as the two
main cell types involved in the pathogenesis of this GN. The
migration and subsequent activation of T lymphocytes and mono-
cytes from the blood throughout the endothelium into the gb-
meruli could be mediated by adhesion molecules present on the
surface of lymphocytes (LFA-1) and endothelial cells (ICAM-1),
and by the chemotactic action of chemokines released by activated
mesangial and epithelial cells. An overexpression of MCP-1 and
RANTES have been detected in glomeruli of patients with
idiopathic CGN [161] and in experimental nephrotoxic nephritis
[155], respectively. In addition, IL-8 expression is increased in the
renal tissue of patients with GN and can be detected in their urine
[162]. The relevance of the chemokines in the pathogenesis of this
peculiar form of GN has been definitely established. Indeed,
Wada et al demonstrated that neutralizing anti-MCP-1 and
anti-IL-8 antibodies can reduce the histologic lesion and improve
the clinical outcome in an experimental model of CGN [163, 164].
Once recruited and activated, both T cells and monocytes can
release IL-i. This cytokine can in turn activate the resident cells
and begin a positive feedback loop, recruiting and activating more
infiltrating cells. IL-i expression has been demonstrated in an
experimental model of CGN [52]. Moreover, the inhibition of
IL-i by the infusion of IL-i receptor antagonist reduces protein-
uria and crescentic lesions in the anti-GBM model of CGN [165].
THE FINAL HAND IN THE GAME
Some forms of primary GN (MCD, mild IgAN) do not present
a progressive feature, and for them the game could continue on
the same table (the gbomerulus) with the same rules and the same
players forever (mild IgAN), or could eventually terminate
(MCD). Other forms progress instead to a common phase played
on a different table, the tubulointerstitial area, and with two new
players, interstitial fibroblast and tubular cells. It is now clear that
in chronic progressive GN the secondary involvement of the
tubulointerstitium is a constant feature and that the degree of
tubulointerstitial lesions correlates with the renal function out-
come better than does the extent of glomerular damage [81.
However, the mechanisms underlying the involvement of the
tubulointerstitium in progressive GN and the consequent inclu-
sion in the game of tubular cells and interstitial fibroblasts are still
largely unknown. Thus, the progression of renal damage in
primary GN, although strongly influenced by the extent of gb-
merulosclerosis, is primarily related to the involvement of tubu-
lointerstitial damage [8]. Several pathogenetic hypotheses have
been proposed for the development of gbomerubosclerosis, which
is the result of chronic glomerular damage [166, 167].
In the hypothesis of progressive mesangiosclerosis, cytokines
and growth factors, released by infiltrating and resident cells, play
an important role. Indeed, the production of these inflammatory
mediators induced by several stimuli may generate a state of
chronic mesangial inflammation that, by inducing a progressive
sclerosis of the mesangial area, culminates in global gbomerubo-
sclerosis. In this hypothesis, PDGF and TGF-p appear to be the
key pathogenetic mediators. The intrarenal infusion of PDGF, in
association with a sub-lytic dose of anti-Thy-I serum, stimulates
the proliferation of mesangial cells and the induction in their
cytoplasm of a-smooth muscle actin (a-SMA), a marker of cell
activation [168]. On the other hand, the in vivo transfection of
TGF-/3 stimulates mesangial cells to synthesize and release extra-
cellular matrix proteins [148]. Moreover, in vivo studies have
demonstrated that TGF-p colocalizes with a-SMA and correlates
with the glomerular deposits of type I and type III collagen [169,
170]. Accumulation of ECM components is further enhanced by
the ability of TGF-f3 to suppress the expression of proteases and
stimulate that of protease inhibitors. In some glomerular diseases,
changes in the expression of metalloproteinases and their inhibi-
tors have been found to correlate negatively or positively with
matrix deposition [171, 172]. However, it should be noted that in
sclerosing gbomerubonephritis there are both qualitative and quan-
titative changes in the expression of ECM components. Moreover,
an altered expression and/or affinity of some matrix receptors in
vivo has been reported, and this could further facilitate the
accumulation of collagen, laminin and fibronectin in sclerosing
lesions [173].
In primary GN, the initial events that activate the local cytokine
and growth factor pathways seem to be prevalently immunological
(that is, circulating immune complexes deposition or their in Situ
formation and consequent complement activation). However,
once the inflammatory process has been primed, other factors,
such as hyperlipidemia and hypertension consequent to nephrotic
proteinuria and renal damage, may contribute to the pathogenesis
of the glomerulosclerosis [174]. Indeed, oxidized LDL as well as
angiotensin II cause chemoattraction of monocytes/macrophages
within the glomerulus, inducing MCP-1 [70, 175], while LDL can
stimulate proliferation and collagen deposition inducing PDGF
and TGF-13 [176].
According to the second hypothesis on the development of
glomerulosclerosis, suggested by Kriz, podocytes may play a
crucial role [167]. Detachment of podocytes from the peripheral
glomerular capillaries, induced by any kind of strain, may denude
the vessel wall that, tending to attach to Bowman's capsule, causes
tuft adhesion. Thus, during a mesangial injury, the glomerular
peripheral capillaries, deprived of their mesangial support, may
lose their centripetal attachment and extend towards the Bow-
man's capsule. Centrifugal expansion and ballooning of these
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Fig. 2. The final pathway. Humoral and
cellular immunity may induce glomerular
damage through the release of cytokines and
growth factors (1st step). Proteinuria
consequent to glomerular damage 179, 1801 or
cytokines released by infiltrating cells and
diffusing from hilar areas of glomeruli [178]
may determine tubular cell activation with
release of chemoattractant substances and
fibrogenic factors (2nd step). Finally, the
activation of interstitial fibroblasts may induce
the increased production of extracellular matrix
(fibronectin, collagen I, III) and fibrosis (3rd
step).
capillaries will be further promoted by the loss of bandaging
support of the podocytes, and eventually result in the apposition
of a "naked" capillary to Bowman's capsule. In our view, while
mesangial cell proliferation is not directly involved in the glomer-
uloscierosis process, podocyte detachment plays a pivotal role.
Thus, the development of sclerosis is not a process of prolifera-
tion, but a process of collapse in which there is a disappearance of
cellular elements and accumulation of hyaline material. The fate
of the glomerulus with initial segmental sclerosis is characterized
by the extension of the sclerotic process to the entire tuft followed
by subsequent migration and colonization of cortical fibroblasts
with deposition of fibrous tissue [167].
As previously reported, in primary GN that progresses together
with the development of glomerulosclerosis, a second inflamma-
tory reaction takes place within the tubulointerstitial compart-
ment (Fig. 2) [1771. Two different models of tubulointerstitial
involvement in glomerular diseases have been proposed. Lan,
Nikolic-Patterson and Atkins suggested that the interstitial in-
flammation may originate from the hilar area of the glomeruli
[178]. The cytokines produced by the mononuclear cells present
within this area could diffuse and induce the up-regulation of
chemokine expression in tubular cells that would in turn be
responsible for the propagation of the infiltrate (Fig. 2). Other
authors have recently proposed an alternative model attributing
the role of messenger inducing tubular cell activation to protein-
uria, consequent to the glomerular damage (Fig. 2) [179, 180].
The possibility that proteinuria may also contribute to the tubu-
lointerstitial injury has been proposed by Rubin-Kelly and Jevni-
kar, who showed that massive protein reabsorption by proximal
tubular cells induces tysosomal activation and, consequently,
antigen presentation followed by cytokine-induced activation of T
helper cells [179]. In contrast, Remuzzi et al suggested that the
increased intracellular trafficking of proteins in the tubules could
activate the transcription factor NF-KB and consequently increase
the expression of a variety of pro-inflammatory genes, inducing
the recruitment of inflammatory cells [180].
In both models proposed, the tubulointerstitial infiltrate may
play a central role in the genesis of the tubular and interstitial
lesions observed in chronic GN. Indeed, different studies report a
strict correlation between tubular atrophy, interstitial fibrosis and
the extent of interstitial infiltrate. This infiltrate is mainly consti-
tuted of a dynamic and active population of cells, predominantly
monocytes and T lymphocytes, that release ROS, cytokines,
growth factors and autacoids which can damage or activate the
adjacent tubular and interstitial cells [181]. Recent studies suggest
that infiltrating immune cells could be recruited within the
interstitial areas by three powerful chemoattractants produced by
activated tubular cells: MCP-1, osteopontin and RANTES [154,
182, 183]. Moreover, Savill, Mooney and Hughes hypothesized
that defective apoptosis could be responsible for the accumulation
of inflammatory cells in the injured kidney, protracting the
inflammation [184]. A number of cytokines and growth factors
could inhibit the apoptosis of the immune cells through inappro-
priate expression of intrinsic survival genes such as bcl-2, or failed
expression of Fas receptor on their surface.
A third key feature of tubulointerstitial inflammation, besides
tubular cell activation and immune cell infiltration, is the presence
and activation of interstitial fibroblasts. Recently, Okada et al
have suggested that interstitial fibroblasts, not generally present in
the normal kidney, could derive from tubular cells through a
process of transdifferentiation (Fig. 3) [185]. Upon stimulation,
epithelial cells may change their phenotype, losing their tendency
to form cuboidal sheets, increasing vimentin production and
decreasing cytokeratin expression. Moreover, the transdifferenti-
ated epithelial cells may express a peculiar cytoplasmic marker of
fibroblast activation: the a-SMA [186]. These activated cells may
proliferate and synthesize extracellular matrix components, play-
ing a major role in the pathogenesis of interstitial fibrosis.
Interstitial fibroblast activation could be mediated by a variety of
soluble factors, including PDGF and TGF-J3 [76, 1871. The latter
is known to activate fibroblasts in vitro and its expression is
increased within the tubulointerstitial compartment in different
models of progressive GN [76, 169, 170]. The former has been
demonstrated in vivo to be effective in inducing a-SMA expres-
sion in interstitial fibroblasts and, concomitantly, interstitial fibro-
sis [187]. Moreover, in animal models and in human studies of GN
different groups have shown a striking up-regulation of PDGF-/3
receptor at interstitial levels that strictly correlated with the extent
of tubulointerstitial lesions [149]. Interestingly, increased expres-
sion of the glycoprotein osteopontin and SPARC at sites of
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Fig. 3. The transdifferentiation hypothesis.
Fibrogenic cytokines and growth factors
released by infiltrating T cells and monocytes/
macrophages may induce the
transdifferentiation of resident cells (tubular
cells and fibroblasts) into myofibroblasts leading
to excessive extracellular matrix production and
consequent interstitial fibrosis [1851.
interstitial injury has been found in experimental animal models
of nephritis and in human glomerulonephritis [188, 189]. Os-
teopontin is synthesized by renal tubular cells and up-regulated in
tubulointerstitial injury [182] while SPARC, also termed Os-
teonectin, modulates angiogenesis and cell proliferation, binds
PDGF and collagen and promotes their deposition [185].
Therapeutic strategies
Once the players, the cards and the rules are known, there is a
good chance of succeeding in influencing the course and outcome
of the different games. What has been done so far, from a
therapeutic point of view, has been to shoot at the players
belonging to the immune system, presuming that their deaths
could have a beneficial effect on the course of glomerular
diseases. Instead, what needs to be done in the near future is to sit
at the same table as the players and try to win the game with
sleight of hand. Below are some tricks that may be used to win the
game.
To stop the cascade of events featuring the inflammatory
process exploding within the glomeruli or later on within the
tubulointerstitial area, the pro-inflammatory signals represented
by cytokines and growth factors must be blocked. The process by
which these short-lived factors are produced and exert their
actions is articulated in three stages: (1) interaction of these
factors with their specific cell-surface receptors; (2) transmission
of the external signal in the cell by the signal transduction process;
(3) synthesis and secretion of cytokines. Therefore, development
of new therapeutic strategies able to interfere with these three
biological events are warranted.
Receptor blockage
A variety of natural and synthetic molecules can inhibit com-
petitively the binding of cytokine and growth factor to their
specific cell-surface receptors, inhibiting their interaction. There
are already a great number of studies using this approach for the
treatment of experimental models of glomerular diseases. Among
the natural inhibitors of cytokine-receptor binding is the IL-i
receptor antagonist (IL-ira) [190]. Studies on specific inhibition
of IL-i activity have been carried out in rats with progressive
crescentic glomerulonephritis by administering a constant infu-
sion of IL-ira [190—1921. This therapy was able to reduce
proteinuria and prevent crescent formation, renal impairment and
renal fibrosis [165, 190]. The beneficial effects of IL-ira were due
to the marked inhibition of glomerular and interstitial ICAM-1
expression, and of the associated glomerular and interstitial
leukocyte infiltration [191, 192].
Besides the natural inhibitors, there are some synthetic mole-
cules, such as trapidil, that can interfere with the receptor binding
of a specific cytokine. This anti-platelet drug has been shown in
vitro to compete with the interaction between PDGF and its
receptor and to inhibit the PDGF mitogenic effect [193]. Its
administration in the anti-Thyi experimental model significantly
improved the clinical and histopathological picture of this model
[194].
Administration of cytokine antagonists
Overexpression of TGF-13 may cause the accumulation of
extracellular matrix (ECM) in GN [153]. Administration of an
antibody against TGF-f3 in rats with mesangioproliferative gb-
merulonephritis has been shown to improve the course of the
disease, preventing ECM production and accumulation in the
injured glomeruli [195]. However, after prolonged therapy with
the antibody it is possible to observe a loss of responsiveness to
TGF-131 caused by a mutation or shedding of TGF-j3 receptors.
For this reason, the same investigators tried to antagonize the
action of TGF-13 in vivo by administrating decorin, a natural
inhibitor of this growth factor, after inducing the same experimen-
tal glomerulonephritis in rats [196]. They obtained a reduced
production of extracellular matrix and attenuation of renal man-
ifestations.
Schena et al: Renal damage progression in glomeru/onephritis 1449
Recombinant protein therapy shows some limits, mainly repre-
sented by the repeated infusion of the highly purified protein. To
overcome these limits, Isaka et al transfected in vivo skeletal
muscle cells with decorin cDNA in rats with the same nephritis,
obtaining comparable results [197]. Decorin cDNA was contained
in liposomes and administered by a single intramuscular injection.
Although, in situ transfection of DNA into skeletal muscle is a
simple and safe way to deliver a protein to the systemic circula-
tion, the long-term consequences of the constant reduction of a
cytokine or growth factor could be harmful as demonstrated by
the TGF-f3 knock-out mice, which die after birth because of an
autoimmune disease [781. Therefore, the possibility of adverse
effect must be carefully evaluated for each cytokine.
Intracellular signaling blockade
The binding of a cytokine or growth factor to its receptor
triggers a cascade of intracellular events causing cell activation or,
in some cases, inhibition. The different receptors can elicit
different intracellular pathways to transduce the signals leading to
the final effect of the specific cytokine. Some of the receptors have
an intrinsic enzymatic activity that, induced by the agonist binding,
triggers the signaling cascade. Other receptors, instead, are asso-
ciated with an enzyme whose activity can be regulated by the
conformational changes of the receptor caused by the interaction
with the agonist. However, the orientation of diverse intracellular
proteins along finely tuned pathways requires the formation of
short-lived protein complexes that relay signals throughout the
cell [198]. Most of the proteins involved have enzymatic activity
and can directly affect the activity of transcription factors, via
protein phosphorylation or dephosphorylation, or indirectly,
through second messengers like phospholipids, calcium and cyclic
nucleotides. Transcription factors should in turn regulate gene
expression and the consequent final cellular responses. This
modular intracellular structure could represent the target of drugs
able to interfere with some of the critical molecular interactions
[198].
Some of these drugs are already being used in everyday clinical
practice, but only recently has their intracellular action begun to
be understood. Among them, ACE inhibitors have been shown to
reduce proteinuria and to slow down the rate of progression of
renal damage in different progressive renal diseases [199, 200].
Besides their action on blood pressure, the drugs of this class,
have been shown to specifically reduce the intracellular calcium
spike induced by PDGF, a key intracellular event in the mitogenic
pathway of this growth factor [201].
Hydroxy methyl-glutaryl CoA (HMGC0A) reductase inhibitors
have been demonstrated to reduce the progression of renal
damage in a variety of experimental models of glomerulosclerosis
[202, 203]. Besides their lipid-lowering effect, in vitro the HMG-
CoA reductase inhibitors can inhibit PDGF-induced mesangial
cell proliferation or LPS-stimulated NF-KB activation in mesan-
gial cell through the inhibition of p21 ras [203, 204]. Ras is a small
GTP-binding protein that plays a centrale role in the signal
transduction pathways of most of the cytokines inducing cell
proliferation and activation [205]. To be functionally active,
however, Ras protein should be linked to specific mevalonate-
derived lipids, geranyl and farnesyl pyrophosphate, whose synthe-
sis is blocked by the HMGCoA reductase inhibition [205].
Glucocorticoids are potent inhibitors of the production of
certain cytokines (IL-I, TNF-a) and chemokines, such as IL-8 and
MCP-1 [206—209]. Most of these genes present in their regulatory
region glucocorticoid responsive elements where the activated
glucocorticoid receptor can bind, down-regulating mRNA tran-
scription. Two other immunosuppressive drugs, cyclosporine A
and FK506, instead bind to calcineurin, which is a critical factor of
the T cell activation pathway regulating the T cell-specific tran-
scription factor, NF-AT [210].
In addition to well-established drugs, there are now an increas-
ing number of compounds targeting critical steps in the signal
transduction pathways that may have therapeutical applications.
Protein kinase C is a cytoplasmic enzyme that is one of the best
known intracellular activators. There is an increasing body of
evidence that the activation of this enzyme, and in particular of its
13 isoform, could be a key event in the pathogenesis of diabetic
nephropathy. Indeed, a specific inhibitor of PKC-J3 can signifi-
cantly reduce glomerular hyperfiltration and microalbuminuria,
two early signs of renal involvement in diabetes [2111.
Another intracellular messenger that has recently received
considerable attention is cAMP. Elevated intracellular levels of
this cyclic nucleotide are always associated with a resting state of
the cell. Therefore, all the compounds that induce the synthesis or
inhibit the degradation of cAMP, deactivating resident and infil-
trating cells, could have a therapeutical relevance [212]. Prosta-
glandins of the E series, and in particular PGE1, are potent
activators of adenylate cyclase and thus induce an increase in
cAMP intracellular concentration [212]. The use of these mole-
cules or of their synthetic analogs has been shown to be extremely
effective in different experimental models of immune-mediated
progressive GN. PGE1 infusion can reduce proteinuria and gb-
merular hypercellularity in nephrotoxic serum nephritis as well as
in the anti-Thyl model of mesangioproliferative GN [213, 214].
Finally, pro-inflammatory cytokines like IL-i and TNF-a exert
their action on several cell types, including mesangial cells, by
inducing the synthesis and activation of phospholipase A2
(PLA2), which generates distal effectors of the inflammatory
injury [215]. The PLA2 inhibition with synthetic molecules like
lipocortin 1, quinacrine hydrochloride and RO 31-4639, therefore,
could attenuate gbomerular as well as tubulointerstitial inflamma-
tion [216—218].
Cytokines and gene therapy
Over the past five years remarkable progress has been made in
the field of gene therapy. Not only have inherited diseases been
treated with gene therapy, but also acquired disorders, such as
cancer and infections, have become candidates for this kind of
therapeutic approach [219, 220]. Successful gene therapy requires
a delivery system by which a particular gene can be introduced
into the desired cell type both efficiently and accurately. Current
strategies involve the use of modified or attenuated retro- or
adenoviruses or DNA-liposome mixtures as vectors for carring the
genetic material into the cell [219]. The best way to achieve the
local production of a specific factor is by ex vivo gene therapy. This
approach consists of removing target cells from the body, intro-
ducing the new genetic material in vitro, and replacing the
"modified" cells in the body, where they can produce the desired
protein. Using the mesangial cell vector as a gene transfer system,
Kitamura et al recently demonstrated that rat mesangial cells,
transfected with TGF-f31 and infused via renal artery injection
into rat kidney affected by anti-Thy-I nephritis, expressed active
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TGF-f31. This contributed to the recovery from the acute glomer-
ular injury by reducing mitogenesis of resident cells, opposing the
effect of local inflammatory cytokines and inhibiting the infiltra-
tion of macrophages that normally accumulate in anti-Thy-i
nephritis [220]. Although the effects of TGF-f31 are contradictory,
this study demonstrates the feasibility of a gene transfer approach
to enable the glomerular cells to produce biologically active
molecules in vivo and to exert control over the activity of immune
mediators involved in glomerular diseases.
In addition to inducing the local production of anti-inflamma-
tory cytokines, the gene therapy approach can also enable local
administration of cytokine antagonist through the local infusion of
cells transfected with the specific antagonist gene. This approach
has recently been applied to immunological diseases such as
rheumatoid arthritis, with intra-articular infusion of synovial cells
producing IL-ira [2211.
While transfecting renal resident cells with specific genes and
introducing them into the kidney it is possible to induce the local
production of the corresponding proteins. Expression of specific
genes in vivo can now be blocked through the use of antisense
oligonucleotides. Antisense oligonucleotides can inhibit the syn-
thesis of a given factor by hybridizing to target sequences within
the mRNA coding for that factor, destabilizing the target mRNA
and consequentely decreasing its translation into protein [2221.
Features that govern the identification of a target site are likely to
be related to the oligonucleotide length and binding affinity and to
the accessibility of the target RNA [222]. Therefore, the oligonu-
cleotides need to be carefully selected in order to find sequences
with the most potent inhibitory action and to avoid non-antisense
effects. Akagi et al have used this therapeutical approach in the
anti-Thyl model in an attempt to block TGF-p expression [223].
The rats treated with TGF-/3 antisense oligonucleotides showed a
reduced expression of this growth factor with a concomitant
reduction in ECM.
Efforts to develop antisense compounds have encountered
some expected problems, such as their quick degradation in vivo
and unexpected side effects such as decreased blood clotting and
increased blood pressure [2241. In addition, many synthetic oligo-
nucleotides, because of their highly negative charge, get hung up
on proteins such as growth factors and anchoring proteins (fi-
bronectin, laminin) outside the cells, interfering with wound
healing and arterial wall repair in living animals [224—226].
An emerging technology in this potential therapeutic field is the
replicative antisense approach in which a gene driven by a strong
viral promoter is inserted into the genome in such a way that the
RNA transcribed from the inserted gene is the opposite, or
"antisense," to the normal "sense" RNA. When the cell tran-
scribes both the sense and antisense genes, the antisense RNA can
interfere with the translation of the sense RNA by binding to it
directly [2271. More animal studies are now warranted to test the
feasibility of this therapeutic approach in vivo.
Administration of cytokines
Another possible strategy aimed at influencing the behavior of
the players throughout the game is that of playing antagonist
cards. The advent of recombinant technology has made large
quantities of highly purified cytokines available for clinical trials.
The progress over the last few years of therapeutic administration
of cytokines alone or in combination with other drugs has yielded
encouraging and exciting results in patients with cancer, inflam-
matory disorders (neurologic diseases, rheumatoid arthritis) and
viral infections, for whom conventional treatments have failed. in
these pathological conditions, the preferential activation of Thi or
Th2 response plays a key pathogenetic role and can be modulated
by administering IL-4 or IFNy, respectively [228]. Recently, IL-12
has been introduced in clinical trials as a drug to fight diseases
characterized by a dominant Th2 profile [229]. In these cases, by
stimulating IFNy production IL-12 induces the differentiation of
Thi cells from uncommitted T cells, and consequently, initiates
cell-mediated immunity. However, therapy with high doses of
cytokines may lead to adverse clinical side effects, like those
experienced with the infusion of high doses of rIL-2 that causes
hypotensive reactions, development of vascular leakage syndrome
induced by activation of the complement system [230], and cardiac
dysfunction [231]. In animal models of GN this therapeutic
approach has already been applied successfully. In an experimen-
tal passive rat model of nephrotoxic nephritis, the intravenous
administration of IL-6 inhibited the effect of LPS and had a
beneficial effect on glomerular injury [232].
Interestingly, it is now possible to administer cytokines orally.
The heavy glycosylation and acid stability of some cytokines may
serve to protect them from the low gastric pH and from complete
proteolysis in intestinal environments [2331. Orally administered
IFN a/ suppressed the development of collagen-induced arthritis
in rats. Oral administration of IFNa may be used in the immu-
noprophylaxis of AIDS and chemokines as blockers of HIV-
infected T cells [234]. However, this therapy may induce side
effects such as leukopenia and depression of granulocyte-mac-
rophage colony forming units in bone marrow. Other cytokines
such as IL-5 and IL-6 have been administered by gavage to mice
for reducing bacterial colonization of peripheral tissues following
hemorrhagic shock and intestinal infections, since IL-6 is able to
restore the compromised intestinal epithelial barrier [233].
Natural cytokines derived from the host species are the best
choice, although questions regarding their purity must always be
raised. Recombinantly-produced cytokines, which are glycosy-
lated, may be an acceptable compromise.
Auto-vaccination
Genetic vaccination by intramuscular injection of naked DNA
encoding a region of the T cell receptor has recently been used by
Waisman et al in mice in experimental autoimmune encephalo-
myelitis [235]. They were able to obtain protection from the
disease, because DNA vaccination induced a shift in the pattern of
T cells cytokine production with a reduction in the Thi cytokines,
IL-2 and IFNY, and an increased expression of IL-4 with a
suppressive effect on the disease. This therapeutic strategy has the
advantage of modulating the cytokine immune response from one
subset to another and may help to suppress the abnormal re-
sponse in disease. The consequence of the introduction of naked
DNA that provides proteins must be better understood, and
methods for controlling immune response need to be developed.
When the naked DNA can be predictably manipulated and
appropriately delivered to achieve the desired outcome of the
disease, we will indeed have entered into the golden age of
vaccination.
Drugs and diet
There are several other strategies that can be used or have
already been used to modify the behavior of the players during the
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games, even if their mechanisms of action are less clear than the
ones previously described.
Some drugs may induce the prevalent production of cytokines
by Thi or Th2 cells, and in diseases with a prevalence of a one cell
subset, the administration of these drugs may cause modification
of this pathological balance. One of these compounds is cipro-
floxacin, a quinolone carboxylic acid derivative that can modulate
the immune response at two levels: the production of IL-2 by
activated T cells and the production of IL-I by activated mono-
cytes/macrophages [236]. The possibility that ciprofloxacin may
react primarily with the IL-2 producing Thi inflammatoiy cells
may indicate the use of this drug in diseases of prevalent function
of Th2 subset.
The beneficial effects of ACE inhibitors in the progression of
renal damage in chronic human glomerulonephritides have been
continuously stressed in this decade, after in vitro studies have
shown that angiotensin II stimulates PDGF and TGF-13 mRNA
expression in cultured mesangial cells [237] and ACE inhibitors
reduce TGF-13 mRNA expression [2381. Clinical trials in primary
and secondary glomerulonephritides have been carried out and
the results obtained showed a decrease in the progression of renal
damage in patients receiving ACE inhibitors or angiotensin II
receptor antagonists [239, 240]. However, in experimental models,
the administration of ACE inhibitors has shown that this drug has
a renoprotective effect when the treatment starts early in the
course of the disease [241].
Low molecular weight heparins (that is, pentosan polysuiphate)
have been proposed to treat proliferative glomerulonephritides,
since they have many anti-inflammatory properties [242] and an
anti-proliferative effect on mesenchymal cells. Interestingly, pen-
tosan polysulphate can block the effects of growth factors like
FGF and TGF-a [243], inhibit complement activation and stop
the release of elastase and other lysosomal enzymes from poly-
morphonuclear cells. Moreover, recently, Rix et al demonstrated
that in vitro heparin can inhibit the ability of IFN7 to stimulate
MHC class II antigens and ICAM-1 expression in endothelial cells
[244].
A low protein diet has long been used as a treatment for slowing
the progression of renal damage, based on the observation that a
reduction in protein intake can decrease glomerular hyperfiltra-
tion. Moreover, Okuda et al recently demonstrated that the
protein-restricted diet can significantly reduce TGF-/3 expression
in rats with mesangioproliferative glomerulonephritis [245].
Plasmapheresis
The use of plasma exchange to treat renal discases was intro-
duced almost twenty years ago and is now gaining new interest
[246]. The rationale in the use of this technique is to rapidly
remove circulating factors known to induce the renal damage.
Plasma exchange, therefore, has been successfully applied, in
association with immunosuppresive therapy, to lowering circulat-
ing titers of autoantibodies, as in anti-GBM nephritis, or immune
complexes [246, 2471. However, in some diseases characterized by
elevated autoantibodies and immune complex titers, such as lupus
nephritis, plasma exchange has been shown to he ineffective [248].
An interesting development of this technique has been the
introduction of immunoadsorbant columns coated with protein A
or the specific antigen recognized by the autoantibody, such as the
u3 chain in the anti-GBM GN, to remove all of the IgG or
specifically the autoantihody [249]. A new frontier for the plasma
exchange has been opened in the treatment of recurrent focal
glomeruloscierosis (FGS), expecially after renal transplantation,
in the attempt to remove the recently isolated circulating perme-
ability factor [110].
Conclusions
It is no surprise that the rapid evolution of biomedical research
over the past few years due to advances in molecular biology
techniques has allowed us to recognize the players, the cards and
probably the rules regulating the different games of human GN.
Moreover, we are now understanding that we could even follow
the game process in the kidney by simply looking at the urinary
excretion of the different soluble mediators, although this hypoth-
esis need to be confirmed in large studies with long-term follow-
up.
However, in the attempt to win the therapeutic game it is
necessary to use sleight of hand to deal the cards. Over the last
few years, many investigators have attempted to block cytokines
and growth factors by applying various therapeutic approaches on
experimental models of progressive glomerulonephritis. Encour-
aging preliminary results have been obtained in experimental
animal models, but the transition from animals to humans re-
quires considerable caution to win the game without organ
damage or loss of life.
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